发炎性肠道疾病市场：依药物类别、适应症、给药途径、通路和地区分类

预计2024年全球发炎性肠道疾病（IBD）市场规模为223.1亿美元，预计到2031年将达301亿美元，2024年至2031年复合年增长率为4.4%。

图：2024 年按地区分類的发炎性肠道疾病市场份额 (%)

发炎性肠道发炎性肠道疾病（IBD）是指克隆氏症和溃疡性大肠炎这两种疾病，其特征是胃肠道内的慢性发炎。 IBD 主要影响小肠和大肠，但有时也会涉及消化器官系统的其他部分。 IBD 的典型症状因患者而异，但通常包括反覆腹痛、腹泻、呕吐、体重减轻和疲劳。儘管确切的原因尚不清楚，但人们认为 IBD 的发生是由于遗传易感患者对环境触发因素的免疫反应调节不当所致。目前可用的治疗方法旨在透过针对免疫系统的各个组成部分来诱导和维持缓解。由于这些治疗方法无法治愈，IBD 在全世界造成了巨大的临床和经济负担。

市场动态：

全球发炎性肠道疾病性肠道疾病市场的成长主要是由于生活方式的改变、环境风险的增加以及已开发国家预期寿命的增加而导致克隆氏症和溃疡性大肠炎盛行率上升。市场成长也受到以下因素的推动：专注于开发新型选择性和个人化疗法的研究活动的活性化、对 IBD 早期诊断和管理的认识不断提高以及主要市场医疗保健成本的上升。然而，严格的药物开发法规以及与 IBD 诊断工具和药物相关的高成本可能会阻碍市场成长。生物製药、干细胞、基因治疗等领域的研究和开发进展可能为相关人员提供利润丰厚的机会。

本研究的主要特点

• 该报告对全球发炎性肠道疾病市场进行了详细分析，以2023年为基准年估计了预测期内（2024-2031年）的市场规模（十亿美元）和年复合成长率（CAGR%）。
• 它还揭示了各个细分市场的潜在商机，并说明了该市场有吸引力的投资提案矩阵。
• 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要见解。
• 该报告的见解将使负责人和公司经营团队能够就未来的产品发布、升级、市场扩张和行销策略做出明智的决策。
• 全球发炎性肠道疾病市场报告迎合了该行业的各个相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
• 透过用于分析全球发炎性肠道疾病市场的各种策略矩阵，将有助于相关人员做出决策。

目录

第一章 研究目的与前提

• 研究目的
• 先决条件
• 简称

第二章 市场展望

• 报告说明
  • 市场定义和范围
• 执行摘要
• Coherent Opportunity Map（COM）

第三章 市场动态、法规与趋势分析

• 市场动态
  • 促进因素
  • 抑制因素
  • 机会
• 影响分析
• 市场趋势
• 主要进展
• 监管场景
• 收购和合作场景
• 资金筹措和投资
• PEST分析
• 波特的分析

第四章全球发炎性肠道疾病市场 - 冠状病毒（COVID-19）大流行的影响

• 整体影响
• 政府倡议
• COVID-19 对市场的影响

第五章全球发炎性肠道疾病市场，依药物类别，2019-2031

• 皮质类固醇
• 氨基胺基
• 肿瘤坏死因子抑制剂
• 免疫抑制剂
• 抗生素
• 其他的

第六章全球发炎性肠道发炎性肠道疾病市场，依疾病分类，2019-2031

• 溃疡性大肠炎
• 克隆氏症

第七章 全球发炎性肠道疾病市场，依给药途径，2019-2031

• 口服
• 可注射的

第8章全球发炎性肠道疾病市场，依通路，2019-2031

• 医院药房
• 零售药房
• 网路药房

第九章全球发炎性肠道疾病市场，按地区，2019-2031

• 拉丁美洲
• 欧洲
• 亚太地区
• 中东

第10章竞争格局

• 公司简介
  • AbbVie Inc.
  • Johnson &Johnson Services, Inc.
  • Takeda Pharmaceutical Company Limited
  • Biogen
  • Amgen Inc.
  • UCB SA
  • Novartis AG
  • Merck &Co., Inc.
  • Pfizer Inc.
  • Eli Lilly and Company
  • Gilead Sciences
  • Bausch Health Companies Inc.
  • Celltrion Healthcare Co., Ltd.
  • CELGENE CORPORATION
  • COSMO PHARMACEUTICALS
  • Innovate Biopharmaceuticals
  • Sandoz
  • Horizon Therapeutics

第十一章分析师建议

• 命运之轮
• 分析师观点
• 一致的机会图

第十二章参考文献与调查方法

• 参考
• 调查方法

Global inflammatory bowel disease market is estimated to be valued at USD 22.31 Bn in 2024 and is expected to reach USD 30.10 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 4.4% from 2024 to 2031.

Figure. Inflammatory Bowel Disease Market Share (%), By Region 2024

Inflammatory bowel disease (IBD) refers to two conditions - Crohn's disease and ulcerative colitis - that are characterized by chronic inflammation within the gastrointestinal tract. IBD predominantly affects the small and large intestines but can sometimes extend throughout other areas of the digestive system. Typical symptoms of IBD vary between patients but often include recurring abdominal pain, diarrhea, vomiting, weight loss, and fatigue. While the precise etiologies remain unclear, IBD is believed to arise due to inappropriately regulated immune responses to environmental triggers in genetically susceptible individuals. Currently available treatment options aim to induce and maintain remission by targeting different components of the immune system. As these approaches are not curative, IBD poses a substantial clinical and economic burden worldwide.

Market Dynamics:

Global inflammatory bowel disease market growth is primarily driven by rising prevalence of Crohn's disease and ulcerative colitis due to lifestyle changes, growing environmental risks, and prolonged lifespan in developed nations. Increasing research activities focused on developing novel selective and personalized therapies, growing awareness about early diagnosis and management of IBD, and rising healthcare expenditure across major markets can also drive the market growth. However, stringent drug development regulations and high costs associated with IBD diagnostic tools and medications can hamper the market growth. Ongoing R&D in biologics, stem cell and gene-based therapies can offer lucrative opportunities for stakeholders.

Key Features of the Study:

• This report provides in-depth analysis of the global inflammatory bowel disease market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• Key companies covered as a part of this study include AbbVie, Janssen Biotech, Takeda Pharmaceutical, UCB, and Pfizer
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global inflammatory bowel disease market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global inflammatory bowel disease market

Detailed Segmentation-

• By Drug Class
  • Corticosteroids
  • Aminosalicylates
  • TNF Inhibitors
  • Immunosuppressant
  • Antibiotics
  • Others
• By Disease Indication
  • Ulcerative Colitis
  • Crohn's Disease
• By Route of Administration
  • Oral
  • Injectable
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • AbbVie Inc.
  • Johnson & Johnson Services, Inc.
  • Takeda Pharmaceutical Company Limited
  • Biogen
  • Amgen Inc.
  • UCB S.A.
  • Novartis AG
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Eli Lilly and Company
  • Gilead Sciences
  • Bausch Health Companies Inc.
  • Celltrion Healthcare Co., Ltd.
  • CELGENE CORPORATION
  • COSMO PHARMACEUTICALS
  • Innovate Biopharmaceuticals
  • Sandoz
  • Horizon Therapeutics

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Class
  • Market Snapshot, By Disease Indication
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Scenario
• Acquisitions and Partnerships Scenario
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Inflammatory Bowel Disease Market- Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global Inflammatory Bowel Disease Market, By Drug Class, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2019 - 2031
  • Segment Trends
• Corticosteroids
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Aminosalicylates
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• TNF Inhibitors
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Immunosuppressant
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Antibiotics
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Inflammatory Bowel Disease Market, By Disease Indication, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2019 - 2031
  • Segment Trends
• Ulcerative Colitis
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Crohn's Disease
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Inflammatory Bowel Disease Market, By Route of Administration, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2019 - 2031
  • Segment Trends
• Oral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Injectable
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global Inflammatory Bowel Disease Market, By Distribution Channel, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2019 - 2031
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

9. Global Inflammatory Bowel Disease Market, By Region, 2019 - 2031, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, For Region, 2019-2031
  • Regional Trends
    • North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
    • Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Bn)
    • North Africa
    • Central Africa
    • South Africa

10. Competitive Landscape

• Company Profiles
  • AbbVie Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Johnson & Johnson Services, Inc.
  • Takeda Pharmaceutical Company Limited
  • Biogen
  • Amgen Inc.
  • UCB S.A.
  • Novartis AG
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Eli Lilly and Company
  • Gilead Sciences
  • Bausch Health Companies Inc.
  • Celltrion Healthcare Co., Ltd.
  • CELGENE CORPORATION
  • COSMO PHARMACEUTICALS
  • Innovate Biopharmaceuticals
  • Sandoz
  • Horizon Therapeutics

11. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

12. References and Research Methodology

• References
• Research Methodology
• About us and Sales Contact